Every material Form 8-K SOLIGENIX, INC. has filed with the SEC since June 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On September 17, 2026, Soligenix stockholders approved raising authorized common shares from 75,000,000 to 125,000,000 and gave the board up to one year to carry out a reverse stock split at a ratio between 1-for-2 and 1-for-20. Stockholders also elected five directors and chose annual advisory votes on executive compensation. Separately, the company increased its at-the-market share sale program with Rodman & Renshaw LLC by $2,500,000, which could add dilution for shareholders.
Authorized common shares rose from 75,000,000 to 125,000,000, effective September 17, 2026 on filing with Delaware.
Board may effect a reverse split of 1-for-2 to 1-for-20 within up to one year, with the ratio set at its discretion.
Five directors elected, including Christopher J. Schaber, PhD, with 2,819,961 votes for; stockholders chose annual advisory votes on executive pay.
At-the-market sales program increased by $2,500,000; about $6,234,000 had been sold under prior supplements covering up to $6,406,000.
Soligenix filed a prospectus supplement on June 26, 2026, raising the maximum aggregate offering amount under its At Market Issuance Sales Agreement with Rodman & Renshaw LLC by $2,500,000. The company previously sold approximately $6,234,000 of shares under prior supplements covering up to $6,406,000. The filing makes additional shares available for sale, which could add to the number of outstanding shares and dilute existing shareholders.
Maximum offering under the Sales Agreement increased by an additional $2,500,000 via a prospectus supplement filed June 26, 2026
Previously sold approximately $6,234,000 of common stock under prior supplements covering up to $6,406,000
Sales Agreement dated January 23, 2026, with Rodman & Renshaw LLC; legal opinion filed as Exhibit 5.1
Soligenix received a Nasdaq notice on June 10, 2026 that its stock has failed the $1.00 minimum bid price requirement, with until December 7, 2026 to regain compliance. The company also ended its HyBryte development program after an interim analysis recommended halting the Phase 3 FLASH2 trial for futility, a move that carries estimated wind-down charges of about $70,000.
Nasdaq notice dated June 10, 2026; the stock stays listed on the Nasdaq Capital Market under SNGX for now.
Compliance deadline is December 7, 2026, 180 calendar days; a second 180-day period may be available under certain conditions.
Board terminated the HyBryte development program on June 11, 2026; wind-down charges estimated at approximately $70,000.
Consulting Chief Medical Officer Richard Straube ceased that role on June 11, 2026; duties move to Medical Director Christopher Pullion.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every SOLIGENIX, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →